Acurx net loss flat at $2.26 million in Q2 2026

• Acurx posted a net loss of $2.26 million for the quarter ended June 30, 2026, little changed from a year earlier.
• R&D expense climbed 104% to $1.07 million, driven by higher manufacturing costs and consulting fees tied to the recurrent CDI program.
• G&A expense fell 29% to $1.24 million on lower professional fees, legal fees, and share-based compensation.
• Cash totaled $10.7 million at June 30, 2026; working capital was $8.2 million.
• April registered direct offering raised about $2.5 million gross, with concurrent 24-month warrants issued for up to 1,650,170 shares at $2.78.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-095904), on August 13, 2026, and is solely responsible for the information contained therein.